FKBP38 deletion exacerbates ConA-induced hepatitis by promoting the immune response through the MCP-1/p38 pathway
- PMID: 38996665
- DOI: 10.1016/j.intimp.2024.112659
FKBP38 deletion exacerbates ConA-induced hepatitis by promoting the immune response through the MCP-1/p38 pathway
Abstract
Autoimmune hepatitis (AIH) is a chronic liver disease characterized by immune dysregulation and hepatocyte damage. FKBP38, a member of the immunophilin family, has been implicated in immune regulation and the modulation of intracellular signaling pathways; however, its role in AIH pathogenesis remains poorly understood. In this study, we aimed to investigate the effects of hepatic FKBP38 deletion on AIH using a hepatic FKBP38 knockout (LKO) mouse model created via cre-loxP technology. We compared the survival rates, incidence, and severity of AIH in LKO mice with those in control mice. Our findings revealed that hepatic FKBP38 deletion resulted in an unfavorable prognosis in LKO mice with AIH. Specifically, LKO mice exhibited heightened liver inflammation and extensive hepatocyte damage compared to control mice, with a significant decrease in anti-apoptotic proteins and a marked increase in pro-apoptotic proteins. Additionally, transcriptional and translational levels of pro-inflammatory cytokines and chemokines were significantly increased in LKO mice compared to control mice. Immunoblot analysis showed that MCP-1 expression was significantly elevated in LKO mice. Furthermore, the phosphorylation of p38 was increased in LKO mice with AIH, indicating that FKBP38 deletion promotes liver injury in AIH by upregulating p38 phosphorylation and increasing MCP-1 expression. Immune cell profiling demonstrated elevated populations of T, NK, and B cells, suggesting a dysregulated immune response in LKO mice with AIH. Overall, our findings suggest that FKBP38 disruption exacerbates AIH severity by augmenting the immune response by activating the MCP-1/p38 signaling pathway.
Keywords: AIH; FK506; FKBP38; Lymphocytes; MCP-1; p38.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Unveiling the interplay between hepatocyte SATB1 and innate immunity in autoimmune hepatitis.Int Immunopharmacol. 2025 Jan 10;144:113712. doi: 10.1016/j.intimp.2024.113712. Epub 2024 Dec 3. Int Immunopharmacol. 2025. PMID: 39626541
-
Multi-Omics Analysis Reveals the Protection of Gasdermin D in Concanavalin A-Induced Autoimmune Hepatitis.Microbiol Spectr. 2022 Oct 26;10(5):e0171722. doi: 10.1128/spectrum.01717-22. Epub 2022 Aug 16. Microbiol Spectr. 2022. PMID: 35972273 Free PMC article.
-
Comparison of Concanavalin a-Induced Murine Autoimmune Hepatitis Models.Cell Physiol Biochem. 2018;46(3):1241-1251. doi: 10.1159/000489074. Epub 2018 Apr 16. Cell Physiol Biochem. 2018. PMID: 29672295
-
Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients.Front Immunol. 2020 Oct 7;11:575572. doi: 10.3389/fimmu.2020.575572. eCollection 2020. Front Immunol. 2020. PMID: 33117375 Free PMC article. Review.
-
Immune mechanisms of Concanavalin A model of autoimmune hepatitis.World J Gastroenterol. 2012 Jan 14;18(2):119-25. doi: 10.3748/wjg.v18.i2.119. World J Gastroenterol. 2012. PMID: 22253517 Free PMC article. Review.
Cited by
-
Angel or devil: the dual roles of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucopyranoside in the development of liver injury based on integrating pharmacological techniques: a systematic review.Front Pharmacol. 2025 Feb 3;16:1523713. doi: 10.3389/fphar.2025.1523713. eCollection 2025. Front Pharmacol. 2025. PMID: 39963244 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous